GlassScriptPhysician profile
Barbara Laman
NPI 1518215078
$3,378.70
in general payments reported to CMS, 2019-2025
32 companies · $587 in 2025
The $587 reported for 2025 was more than what 75% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $960 · 2022: $811 · 2023: $583 · 2024: $438 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $486.44 | 2021-2025 | Dysport |
| Abbvie INC. | $466.24 | 2022-2025 | |
| Radius Health, INC. | $384.85 | 2021-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $277.64 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $261.29 | 2021-2022 | |
| Amgen INC. | $209.51 | 2021-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $145.19 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $138.55 | 2021-2025 | Xtampza, Belbuca |
| Merz Pharmaceuticals, LLC | $108.94 | 2022-2025 | Xeomin |
| Amneal Pharmaceuticals LLC | $101.34 | 2022-2023 | Lioresal (Baclofen), Lyvispah |
| Otsuka America Pharmaceutical, INC. | $98.69 | 2023-2025 | Nuedexta |
| Astrazeneca Pharmaceuticals LP | $76.06 | 2021-2022 | |
| Pacira Therapeutics, INC. | $73.30 | 2021 | |
| Nevro Corp. | $52.89 | 2021 | |
| Saol Therapeutics INC. | $48.96 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $48.44 | 2023-2024 | Briviact |
| Protega Pharmaceutials INC | $40.73 | 2022 | |
| Boston Scientific Corporation | $39.37 | 2024 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $35.31 | 2022-2025 | Teriparatide |
| Ibsa Pharma INC. | $31.09 | 2023 | Tirosint, Licart |
| Grt US Holding, INC. | $28.98 | 2021 | |
| Scilex Pharmaceuticals INC. | $26.43 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.23 | 2021 | |
| Microtransponder, INC. | $21.20 | 2025 | |
| Abbott Laboratories | $20.83 | 2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.53 | 2022 | |
| Tersera Therapeutics LLC | $20.41 | 2025 | Prialt |
| Vertex Pharmaceuticals Incorporated | $19.89 | 2025 | |
| Kyowa Kirin, INC. | $18.71 | 2024 | Crysvita |
| Dentsply Ih Ab | $18.10 | 2024 | Navina Rectal Catheter Set Regular |
| Medtronic, INC. | $18.09 | 2025 | Kyphon Express II Kyphopak Tray |
| Alexion Pharmaceuticals, INC. | $17.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Laman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.